Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype Oxford Asthma Attack Risk Scale (ORACLE).

Simon Couillard William Il Hoon Do Richard Beasley Timothy Stopford Christopher Hinks Ian Douglas Pavord

Published in: ERJ open research (2021)

The prototype ORACLE scale based on two simple measures of type 2 airway inflammation (blood eosinophils and F ENO ) quantifies the excess risk conferred by raised biomarkers that is removed by type-2 anti-inflammatory treatment in trial populations https://bit.ly/3F1gnUl.

Keyphrases

anti inflammatory
chronic obstructive pulmonary disease
clinical trial
study protocol
lung function
open label
replacement therapy
phase iii
phase ii